text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

LDN-22684: A LRRK2 Inhibitor as a Useful Tool for the Study of Parkinson's Disease

The leucine-rich repeat kinase 2 (LRRK2) is a large protein (2527 amino acids) with serine-threonine (Ser/Thr) protein kinase activity and autophosphorylation activity. It is highly expressed in many mammal tissues. Genetic mutations in the G2019S encoding portion of LRRK2 (LRRK2-G2019S) have been frequently detected in patients with Parkinson's disease (PD).1-3) As a result, inhibitors targeting LRRK2 (especially those selective for the G2019S variant) have been increasingly researched recently not only as a treatment for familial PD, but also as a useful tool to study LRRK2 functions. It is reported that LDN-22684 (1) inhibited LRRK2-G2019S and wild-type LRRK2 in the micromolar range.1,3) Therefore, 1 is regarded as a useful tool for the study of PD.

Schematic of LRRK2 protein structure with reported PD pathogenic familial mutations (red).2)

Related Products

L0422
LDN-22684

Product Category Page

References

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.